Ecker Robert D, Lau Tsz, Levy Elad I, Hopkins L Nelson
Millard Fillmore Gates Hospital, Kaleida Health, 14209, USA.
J Neurosurg. 2007 Feb;106(2):217-21. doi: 10.3171/jns.2007.106.2.217.
There is no known standard 30-day morbidity and mortality rate for high-risk patients undergoing carotid artery (CA) angioplasty and stent (CAS) placement. The high-risk registries and the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy, Carotid Revascularization using Endarterectomy or Stenting Systems, and European Long-term Carotid Artery Stenting trials report different rates of morbidity and mortality, and each high-risk cohort has a different risk profile. The applicability of carotid endarterectomy (CEA) results from North American Symptomatic Carotid Endarterectomy Trial/Asymptomatic Carotid Atherosclerosis Study (NASCET/ACAS) remains uncertain, as most clinical CAS placement series reported to date typically included patients who would not have qualified for those studies. At the University at Buffalo, the same neurosurgeons perform triage in patients with CA disease and perform both CEA and CAS insertion. The authors review morbidity and mortality rates in this practice model.
Diagnosis-related group codes were used to search the authors' practice database for patients who had undergone a completed CA intervention solely for the indication of atherosclerotic disease. One hundred twenty patients (129 vessels) treated with CAS surgery and 95 patients (100 vessels) treated with CEA met these criteria. In the CAS placement group, 78% of the patients would not have met NASCET/ACAS inclusion criteria. Demographic and clinical data for both groups were recorded on a spreadsheet for analysis. At 30 days, one patient in the CEA group and two in the CAS group had died. Stroke occurred in one patient in the CAS group and none in the CEA group. Myocardial infarction (MI) occurred in one patient who underwent CAS surgery compared with three undergoing CEA. Composite incidence of stroke/death/MI was 3.3% in the CAS group and 3.2% in the CEA group.
In a practice in which surgeons perform both CEA and CAS surgery, the event rates for the CAS surgery equivalent to NASCET and ACAS rates for CEA can be achieved, even in high-risk NASCET/ACAS-ineligible patients in 78% of the CAS cases.
对于接受颈动脉(CA)血管成形术和支架置入术(CAS)的高危患者,目前尚无已知的30天发病率和死亡率标准。高危登记研究以及高危内膜切除术患者的血管成形术和支架置入术、使用内膜切除术或支架系统的颈动脉血运重建术和欧洲长期颈动脉支架置入术试验报告的发病率和死亡率有所不同,且每个高危队列的风险特征也不同。北美症状性颈动脉内膜切除术试验/无症状颈动脉粥样硬化研究(NASCET/ACAS)中颈动脉内膜切除术(CEA)的结果适用性仍不确定,因为迄今报道的大多数临床CAS置入系列通常纳入了不符合这些研究条件的患者。在布法罗大学,同一组神经外科医生对CA疾病患者进行分诊,并实施CEA和CAS置入手术。作者回顾了这种实践模式下的发病率和死亡率。
使用诊断相关组代码在作者的实践数据库中搜索仅因动脉粥样硬化疾病指征而接受完整CA干预的患者。120例接受CAS手术治疗的患者(129条血管)和95例接受CEA治疗的患者(100条血管)符合这些标准。在CAS置入组中,78%的患者不符合NASCET/ACAS纳入标准。两组的人口统计学和临床数据记录在电子表格中进行分析。30天时,CEA组有1例患者死亡,CAS组有2例患者死亡。CAS组有1例患者发生卒中,CEA组无卒中发生。接受CAS手术的患者中有1例发生心肌梗死(MI),而接受CEA的患者中有3例发生MI。CAS组卒中/死亡/MI的综合发生率为3.3%,CEA组为3.2%。
在外科医生同时实施CEA和CAS手术的实践中,可以实现与NASCET中CEA发生率相当的CAS手术事件发生率,即使在78%的CAS病例中为不符合NASCET/ACAS标准的高危患者。